Acurx Pharmaceuticals Analyst Ratings
Acurx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 642.86% | HC Wainwright & Co. | → $13 | Reiterates | Buy → Buy |
| 08/15/2023 | 642.86% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/15/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 04/11/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 03/17/2023 | 700% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 12/19/2022 | 700% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 10/20/2022 | 700% | Alliance Global Partners | → $14 | Initiates Coverage On | → Buy |
| 11/29/2021 | 585.71% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/13/2023 | 642.86% | HC Wainwright公司 | →$13 | 重申 | 购买→购买 |
| 2023年08月15日 | 642.86% | HC Wainwright公司 | $14→$13 | 维护 | 买 |
| 2023年05月15日 | 700% | HC Wainwright公司 | →$14 | 重申 | 购买→购买 |
| 04/11/2023 | 700% | HC Wainwright公司 | →$14 | 重申 | →购买 |
| 03/17/2023 | 700% | HC Wainwright公司 | →$14 | 重申 | →购买 |
| 2022年12月19日 | 700% | HC Wainwright公司 | →$14 | 开始承保 | →购买 |
| 10/20/2022 | 700% | 联盟全球合作伙伴 | →$14 | 开始承保 | →购买 |
| 2021年11月29日 | 585.71% | Maxim集团 | →$12 | 开始承保 | →购买 |
What is the target price for Acurx Pharmaceuticals (ACXP)?
Acurx制药公司(ACXP)的目标价是多少？
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on September 13, 2023. The analyst firm set a price target for $13.00 expecting ACXP to rise to within 12 months (a possible 642.86% upside). 7 analyst firms have reported ratings in the last year.
阿科克斯制药公司(纳斯达克代码：ACXP)的最新目标价是由HC Wainwright&Co.于2023年9月13日报道的。这家分析公司将目标价定为13美元，预计ACXP将在12个月内上涨(可能上涨642.86%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Acurx Pharmaceuticals (ACXP)?
分析师对Acurx制药公司(ACXP)的最新评级是多少？
The latest analyst rating for Acurx Pharmaceuticals (NASDAQ: ACXP) was provided by HC Wainwright & Co., and Acurx Pharmaceuticals reiterated their buy rating.
分析师对艾柯克制药(纳斯达克代码：ACXP)的最新评级由HC Wainwright&Co.提供，艾柯克斯制药重申其买入评级。
When is the next analyst rating going to be posted or updated for Acurx Pharmaceuticals (ACXP)?
Acurx PharmPharmticals(ACXP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acurx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acurx Pharmaceuticals was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Acurx制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Acurx制药的上一次评级是在2023年9月13日提交的，所以你应该预计下一次评级将在2024年9月13日左右的某个时候公布。
Is the Analyst Rating Acurx Pharmaceuticals (ACXP) correct?
分析师对Acurx制药公司(ACXP)的评级正确吗？
While ratings are subjective and will change, the latest Acurx Pharmaceuticals (ACXP) rating was a reiterated with a price target of $0.00 to $13.00. The current price Acurx Pharmaceuticals (ACXP) is trading at is $1.75, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Acurx制药(ACXP)评级被重申，目标价在0.00美元至13.00美元之间。Acurx PharmPharmticals(ACXP)目前的交易价格为1.75美元，在分析师的预测范围内。